The Future of Drug Repositioning: Old Drugs, New Opportunities

Publisher Summary This chapter summarizes some of the novel methods used to accelerate the discovery of old drugs that could potentially treat new indications, either by the established mechanism of action or by the identification of new ones. Representative case studies of the approaches to therapeutic discoveries are also highlighted. Researchers have previously identified repositioned drugs by serendipity, novel insights, or target searching. The innovative strategies directed toward drug repositioning discussed in this chapter are phenotypic, high throughput, and in silico screening of commercial, public, and pharmaceutical compound libraries, the prospective mining of drug/activity databases, the exchange of compound information in collaborative networks, and data collection from the Internet and social networks. The term “drug repositioning” has been used interchangeably with “drug repurposing” or “drug reprofiling,” which is a promising field in drug discovery that identifies new therapeutic opportunities for existing drugs.

[1]  Michael Karin,et al.  The IKK NF-κB system: a treasure trove for drug development , 2004, Nature Reviews Drug Discovery.

[2]  Michelle R. Arkin,et al.  Image-Based High-Throughput Drug Screening Targeting the Intracellular Stage of Trypanosoma cruzi, the Agent of Chagas' Disease , 2010, Antimicrobial Agents and Chemotherapy.

[3]  E. Tobinick The value of drug repositioning in the current pharmaceutical market. , 2009, Drug news & perspectives.

[4]  Tudor I. Oprea,et al.  Flow cytometry for high-throughput, high-content screening. , 2004, Current opinion in chemical biology.

[5]  Donald Wlodkowic,et al.  Microfluidics: Emerging prospects for anti-cancer drug screening. , 2010, World journal of clinical oncology.

[6]  T. Hideshima,et al.  Thalidomide in multiple myeloma. , 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  L. Zon,et al.  In vivo drug discovery in the zebrafish , 2005, Nature Reviews Drug Discovery.

[8]  Andrew L. Hopkins,et al.  Chemical Tools for Indications Discovery , 2005 .

[9]  M. Boguski,et al.  Repurposing with a Difference , 2009, Science.

[10]  J. Hevel,et al.  Tissue injury caused by deposition of immune complexes is L-arginine dependent. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Cavalla APT drug R&D: the right active ingredient in the right presentation for the right therapeutic use , 2009, Nature Reviews Drug Discovery.

[12]  Jun O. Liu,et al.  A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.

[13]  G. Plosker Aztreonam Lysine for Inhalation Solution , 2010, Drugs.

[14]  Roland Zengerle,et al.  Microfluidic platforms for lab-on-a-chip applications. , 2007, Lab on a chip.

[15]  R Abagyan,et al.  Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs , 2007, Proceedings of the National Academy of Sciences.

[16]  M. Detke,et al.  Efficacy and Safety of Duloxetine in Patients With Chronic Low Back Pain , 2010, Spine.

[17]  Philip E. Bourne,et al.  PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..

[18]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[19]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[20]  S. Patterson,et al.  Exploiting Drug Repositioning for Discovery of a Novel HIV Combination Therapy , 2010, Journal of Virology.

[21]  M. C. Okafor Thalidomide for Erythema Nodosum Leprosum and Other Applications , 2003, Pharmacotherapy.

[22]  E. Kunkel Systems biology in drug discovery , 2004, Nature Biotechnology.

[23]  M. Detke,et al.  Effects of duloxetine on painful physical symptoms associated with depression. , 2004, Psychosomatics.

[24]  M. Tsang Zebrafish: A tool for chemical screens. , 2010, Birth defects research. Part C, Embryo today : reviews.

[25]  R. N. Brogden,et al.  Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. , 1986, Drugs.

[26]  Calum A. MacRae,et al.  Drugs That Induce Repolarization Abnormalities Cause Bradycardia in Zebrafish , 2003, Circulation.

[27]  Ruili Huang,et al.  Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. , 2010, Biochemical pharmacology.

[28]  J. Medina-Franco,et al.  The prince and the pauper. A tale of anticancer targeted agents , 2008, Molecular Cancer.

[29]  J. Falgueyret,et al.  Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms. , 2004, The Biochemical journal.

[30]  J. Bajorath,et al.  Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.

[31]  Angeleen Fleming,et al.  Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects , 2010, Neuropharmacology.

[32]  E. Schadt,et al.  Integrative genomics and drug development. , 2009, Pharmacogenomics.

[33]  Ruedi Stoop,et al.  An Ontology for Pharmaceutical Ligands and Its Application for in Silico Screening and Library Design , 2002, J. Chem. Inf. Comput. Sci..

[34]  A. V. van Oosterom,et al.  Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma , 2008 .

[35]  R. Zengerle,et al.  Microfluidic lab-on-a-chip platforms: requirements, characteristics and applications. , 2010, Chemical Society reviews.

[36]  黄亚明 MedScape , 2009 .

[37]  Neil Seeman,et al.  A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants. , 2011, Journal of affective disorders.

[38]  Maria Paola Costi,et al.  Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase. , 2011, Journal of medicinal chemistry.

[39]  Bharat B. Aggarwal,et al.  Nuclear factor-κB: its role in health and disease , 2004, Journal of Molecular Medicine.

[40]  Xiaoyan Wang,et al.  Active computerized pharmacovigilance using natural language processing, statistics, and electronic health records: a feasibility study. , 2009, Journal of the American Medical Informatics Association : JAMIA.

[41]  A. Fliri,et al.  Drug effects viewed from a signal transduction network perspective. , 2009, Journal of medicinal chemistry.

[42]  Gordon A. Leonard,et al.  Pteridine reductase mechanism correlates pterin metabolism with drug resistance in trypanosomatid parasites , 2001, Nature Structural Biology.

[43]  Lisa Jarvis OPENING THE MEDICINE CABINET , 2010 .

[44]  Camille G Wermuth,et al.  Selective optimization of side activities: the SOSA approach. , 2006, Drug discovery today.

[45]  K. Heyne,et al.  Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). , 1975, Pediatrics.

[46]  David W Carley,et al.  Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part I. , 2005, IDrugs : the investigational drugs journal.

[47]  Tom F. Lue,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, New England Journal of Medicine.

[48]  S. Mignani,et al.  Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. , 1999, Journal of medicinal chemistry.

[49]  Joseph M. Tonning,et al.  Perspectives on the Use of Data Mining in Pharmacovigilance , 2005, Drug safety.

[50]  S. Sleigh,et al.  Repurposing Strategies for Therapeutics , 2010, Pharmaceutical Medicine.

[51]  Neil Seeman,et al.  Assessing and responding in real time to online anti-vaccine sentiment during a flu pandemic. , 2010, Healthcare quarterly.

[52]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[53]  M. Backonja,et al.  Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study. , 2010, Pain medicine.